PG
ALNY icon

Proffitt & Goodson’s Alnylam Pharmaceuticals ALNY Stock Holding History

Proffitt & Goodson’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23
Closed -$9.15K – 290
2025
Q4 		$9.15K Sell
23
-1
-4% -$443 ﹤0.01% 232
2025
Q3 		$10.9K Buy
+24
New +$9.77K ﹤0.01% 243

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Proffitt & Goodson's ALNY Position: Q1 2026 in Review

Proffitt & Goodson sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 23 shares — an estimated $9.15K sold.

Proffitt & Goodson first reported a position in ALNY in Q3 2025 and held it in 2 quarters. The position peaked at $10.9K in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Proffitt & Goodson reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Proffitt & Goodson sold 23 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $9.15K.
  • Proffitt & Goodson first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Proffitt & Goodson's Alnylam Pharmaceuticals position peaked at $10.9K in Q3 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Proffitt & Goodson's 13F filing for Q1 2026, filed 6 May 2026.